Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

[Nursing role and risk reduction for drug users].

Denize Y, Humbert S, Laborde A, Kreiss A, Waeckerlé G.

Rev Infirm. 2018 Jan;67(237):22-24. doi: 10.1016/j.revinf.2017.11.004. French.

PMID:
29331187
2.

Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.

Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, Malley RC, Siddle HV, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss AT, Corcoran LM, Murphy JM, Pearse MJ, Belov K, Lyons AB, Woods GM.

Sci Rep. 2017 Mar 9;7:43827. doi: 10.1038/srep43827.

3.

Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM.

Biol Lett. 2016 Oct;12(10). pii: 20160553. doi: 10.1098/rsbl.2016.0553.

4.

Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, Corcoran LM, Bettiol SS, Lyons AB, Woods GM.

Immunol Cell Biol. 2016 Aug;94(7):673-9. doi: 10.1038/icb.2016.38. Epub 2016 Apr 19.

PMID:
27089941
5.

A second transmissible cancer in Tasmanian devils.

Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, Fox S, Darby J, Hayes D, Knowles GW, Kreiss A, Siddle HV, Swift K, Lyons AB, Murchison EP, Woods GM.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):374-9. doi: 10.1073/pnas.1519691113. Epub 2015 Dec 28.

6.

Devil Facial Tumor Disease.

Pye RJ, Woods GM, Kreiss A.

Vet Pathol. 2016 Jul;53(4):726-36. doi: 10.1177/0300985815616444. Epub 2015 Dec 13. Review.

PMID:
26657222
7.

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.

Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, Lyons AB.

J Immunol. 2015 Jul 1;195(1):23-9. doi: 10.4049/jimmunol.1500131. Review.

8.

Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.

Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM.

Vaccine. 2015 Jun 12;33(26):3016-25. doi: 10.1016/j.vaccine.2015.01.039. Epub 2015 Feb 20.

9.

Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors.

Howson LJ, Morris KM, Kobayashi T, Tovar C, Kreiss A, Papenfuss AT, Corcoran L, Belov K, Woods GM.

Anat Rec (Hoboken). 2014 May;297(5):925-38. doi: 10.1002/ar.22904. Epub 2014 Mar 24.

10.

Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.

Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, Swift K, Pearse AM, Hamede R, Jones ME, Skjødt K, Woods GM, Kaufman J.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5103-8. doi: 10.1073/pnas.1219920110. Epub 2013 Mar 11.

11.

Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer.

Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, Fu B, Hims M, Ding Z, Ivakhno S, Stewart C, Ng BL, Wong W, Aken B, White S, Alsop A, Becq J, Bignell GR, Cheetham RK, Cheng W, Connor TR, Cox AJ, Feng ZP, Gu Y, Grocock RJ, Harris SR, Khrebtukova I, Kingsbury Z, Kowarsky M, Kreiss A, Luo S, Marshall J, McBride DJ, Murray L, Pearse AM, Raine K, Rasolonjatovo I, Shaw R, Tedder P, Tregidgo C, Vilella AJ, Wedge DC, Woods GM, Gormley N, Humphray S, Schroth G, Smith G, Hall K, Searle SM, Carter NP, Papenfuss AT, Futreal PA, Campbell PJ, Yang F, Bentley DR, Evers DJ, Stratton MR.

Cell. 2012 Feb 17;148(4):780-91. doi: 10.1016/j.cell.2011.11.065.

12.

Reduced effect of Tasmanian devil facial tumor disease at the disease front.

Hamede R, Lachish S, Belov K, Woods G, Kreiss A, Pearse AM, Lazenby B, Jones M, McCallum H.

Conserv Biol. 2012 Feb;26(1):124-34. doi: 10.1111/j.1523-1739.2011.01747.x. Epub 2011 Oct 6.

PMID:
21978020
13.

Natural killer cell mediated cytotoxic responses in the Tasmanian devil.

Brown GK, Kreiss A, Lyons AB, Woods GM.

PLoS One. 2011;6(9):e24475. doi: 10.1371/journal.pone.0024475. Epub 2011 Sep 21.

14.

Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity.

Kreiss A, Cheng Y, Kimble F, Wells B, Donovan S, Belov K, Woods GM.

PLoS One. 2011;6(7):e22402. doi: 10.1371/journal.pone.0022402. Epub 2011 Jul 21.

15.

Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil).

Miller W, Hayes VM, Ratan A, Petersen DC, Wittekindt NE, Miller J, Walenz B, Knight J, Qi J, Zhao F, Wang Q, Bedoya-Reina OC, Katiyar N, Tomsho LP, Kasson LM, Hardie RA, Woodbridge P, Tindall EA, Bertelsen MF, Dixon D, Pyecroft S, Helgen KM, Lesk AM, Pringle TH, Patterson N, Zhang Y, Kreiss A, Woods GM, Jones ME, Schuster SC.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12348-53. doi: 10.1073/pnas.1102838108. Epub 2011 Jun 27. Erratum in: Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18625.

16.

Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies.

Tovar C, Obendorf D, Murchison EP, Papenfuss AT, Kreiss A, Woods GM.

Vet Pathol. 2011 Nov;48(6):1195-203. doi: 10.1177/0300985811400447. Epub 2011 Mar 7.

PMID:
21383118
17.

A murine xenograft model for a transmissible cancer in Tasmanian devils.

Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM.

Vet Pathol. 2011 Mar;48(2):475-81. doi: 10.1177/0300985810380398. Epub 2010 Sep 22.

PMID:
20861503
18.

The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer.

Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, Kreiss A, Kellis M, Stark A, Harkins TT, Marshall Graves JA, Woods GM, Hannon GJ, Papenfuss AT.

Science. 2010 Jan 1;327(5961):84-7. doi: 10.1126/science.1180616.

19.

A histological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil.

Kreiss A, Obendorf DL, Hemsley S, Canfield PJ, Woods GM.

Anat Rec (Hoboken). 2009 May;292(5):611-20. doi: 10.1002/ar.20896.

20.

The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells.

Kreiss A, Wells B, Woods GM.

Vet Immunol Immunopathol. 2009 Jul 15;130(1-2):135-7. doi: 10.1016/j.vetimm.2009.02.003. Epub 2009 Feb 11.

PMID:
19264365
21.

Mitogen-induced responses in lymphocytes from platypus, the Tasmanian devil and the eastern barred bandicoot.

Stewart NJ, Bettiol SS, Kreiss A, Fox N, Woods GM.

Aust Vet J. 2008 Oct;86(10):408-13. doi: 10.1111/j.1751-0813.2008.00349.x.

PMID:
18826514
22.

[Reflections no humanitarian engagement].

Courcol W, El Homrani F, Geber M, Gebhart D, Helmstetter C, Kreiss A, Leininger C, Leroux S, Mazouzi J, Noudjou J, Altmayer A, Anfray V, Bozarhoun MA, Chartier C, Christen P, De Surmont R, Djouder J, Felder E, Freire MC, Ghazal H, Gnaedig E, Hauchard F, Heiligenstein L, Keck C, Lievre D, Messas H, Paczek C, Vinson M.

Rev Infirm. 2008 Jun;(141):39-40. French. No abstract available.

PMID:
18669388
23.

Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.

Layer P, Keller J, Loeffler H, Kreiss A.

Ther Clin Risk Manag. 2007 Mar;3(1):107-18.

24.

Preemptive versus postoperative lumiracoxib for analgesia in ambulatory arthroscopic knee surgery.

Grifka J, Enz R, Zink J, Hugot JL, Kreiss A, Arulmani U, Yu V, Rebuli R, Krammer G.

J Pain Res. 2008 Nov 1;1:27-34.

25.

Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii).

Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM.

Dev Comp Immunol. 2008;32(5):544-53. Epub 2007 Oct 16.

PMID:
17988737
26.

Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial.

Siddle HV, Kreiss A, Eldridge MD, Noonan E, Clarke CJ, Pyecroft S, Woods GM, Belov K.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16221-6. Epub 2007 Oct 2.

27.

Effect of PJ-34 PARP-inhibitor on rat liver microcirculation and antioxidant status.

Szijártó A, Batmunkh E, Hahn O, Mihály Z, Kreiss A, Kiss A, Lotz G, Schaff Z, Váli L, Blázovics A, Geró D, Szabó C, Kupcsulik P.

J Surg Res. 2007 Sep;142(1):72-80. Epub 2007 Jul 5.

PMID:
17612561
28.

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.

Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, Litschig S, Krammer G, Tate GA.

Rheumatology (Oxford). 2007 Jul;46(7):1126-32. Epub 2007 May 3.

PMID:
17478464

Supplemental Content

Loading ...
Support Center